The $540m venture financing of Noom was the medical devices industry’s top cross border venture financing deal as total deals worth $1.7bn were announced globally in May 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 72.9% over the previous month of $983.21m and a rise of 250.3% when compared with the last 12-month average, which stood at $485.27m.
Comparing cross border venture financing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.1bn. At the country level, the US topped the list in terms of deal value at $1.1bn.
In terms of volumes, North America emerged as the top region for medical devices industry cross border venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of cross border venture financing deals activity in May 2021 was the US with 13 deals, followed by the UK with six and China with three.
In 2021, as of May, medical devices cross border venture financing deals worth $3.86bn were announced globally, marking an increase of 73.3% year on year.
medical devices industry cross border venture financing deals in May 2021: Top deals
The top five medical devices industry cross border venture financing deals accounted for 64.01% of the overall value during May 2021.
The combined value of the top five medical devices cross border venture financing deals stood at $1.09bn, against the overall value of $1.7bn recorded for the month.
The top five medical devices industry cross border venture financing deals of May 2021 tracked by GlobalData were:
1) Novo Holdings, Oak HC/FT Partners, RRE Ventures, Samsung Ventures Investment, Sequoia Capital Operations, Silver Lake Management and Temasek Holdings (Private)’s $540m venture financing of Noom
2) The $200m venture financing of Esco Micro by China Investment, EDBI, Novo Holdings and Vivo Capital
3) HAT SGR, Hitachi Ventures, Leaps by Bayer, Samsung NEXT Fund, Sony Innovation Fund and Unilever Ventures’ $130m venture financing of Huma Therapeutics
4) The $110m venture financing of Vida Health by AME Cloud Ventures, Ardea Partners, Aspect Ventures, AXA Venture Partners, Canvas Ventures, Centene, General Atlantic, NGP Capital and Workday Ventures
5) Amgen Ventures, Baillie Gifford, Canepa Healthcare, Dave Baszucki, Fearless Ventures, Jazz Venture Partners, Ladera Venture Partners, M Ventures, Mirae Asset Securities, Neuberger Berman Group, New Leaf Venture Partners, Omidyar Technology Ventures, Polaris Partners, Quad Investment Management, ShionogiLtd and Temasek Holdings (Private)’s venture financing of Akili Interactive Labs for $110m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.